DARPA Press Release
LBG has been recognized for its role in an innovative program in a press release titled “DARPA Team Begins Work on Field Deployable Whole Blood Equivalent.”
Recently issued by DARPA, the release discusses DARPA’s Fieldable Solutions for Hemorrhage with bio-Artificial Resuscitation Products (FSHARP) program, which “aims to develop a field-deployable, shelf-stable whole blood equivalent that can be used to resuscitate trauma patients when donated blood products are not available.”
As part of the team that DARPA selected at the University of Maryland, Baltimore (UMB) to lead this effort, LBG contributed its expertise by leading and supporting the pre-award phase of the program, including leading the proposal effort for UMB and supporting contracting and negotiations. LBG will support the execution of the program by providing program management, nonclinical subject matter expertise, regulatory strategy, and cost modeling.
“We are extremely honored to be part of such a groundbreaking and disruptive program comprised of an all-star team of innovators,” says DJ Rezac, Ph.D., Associate Director and leader of the LBG FSHARP team. “If successful, FSHARP will close the gap that exists on the battlefield and beyond for a fieldable, logistically sustainable, and physiologically comprehensive replacement for donor-derived whole blood. This is the type of endeavor where the impact of the team’s success will never be in question as we strive to fundamentally change the landscape of trauma medicine and combat casualty care.”
